Status:
COMPLETED
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults
Lead Sponsor:
Sinovac Research and Development Co., Ltd.
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this stud...
Detailed Description
This study is a multi-center and open design, phase Ⅳ clinical trial in population aged 18 years years and older. The experimental vaccine will be manufactured by Sinovac Research and Development Co.,...
Eligibility Criteria
Inclusion
- Have not received any COVID-19 vaccine in the past or at least one dose of CoronaVac manufactured by Sinovac Research and Development Co.,Ltd;
- Population aged 18 years and above;
- The subjects can understand and voluntarily sign the informed consent form and participate in the follow-up;
Exclusion
- History of severe allergy to the vaccine such as acute allergic reaction,angioedema and dyspnea ;
- Severe neurological disease such as transverse myeliti,Guillain-Barre Syndrome and demyelinating disorders;
- Acute diseas,acute onset of chronic disease and severe chronic diseases.
Key Trial Info
Start Date :
June 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2023
Estimated Enrollment :
131650 Patients enrolled
Trial Details
Trial ID
NCT04911790
Start Date
June 5 2021
End Date
August 31 2023
Last Update
September 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yongping Center for Diseases Control and Prevention
Dali, Yunnan, China, 650022